CA3138180A1 - Dosage regimens for and compositions including anti-rsv antibodies - Google Patents

Dosage regimens for and compositions including anti-rsv antibodies Download PDF

Info

Publication number
CA3138180A1
CA3138180A1 CA3138180A CA3138180A CA3138180A1 CA 3138180 A1 CA3138180 A1 CA 3138180A1 CA 3138180 A CA3138180 A CA 3138180A CA 3138180 A CA3138180 A CA 3138180A CA 3138180 A1 CA3138180 A1 CA 3138180A1
Authority
CA
Canada
Prior art keywords
rsv
patient
antigen binding
binding fragment
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3138180A
Other languages
English (en)
French (fr)
Inventor
Anis Ahmed KHAN
Vadryn PIERRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Sanofi Pasteur Inc
Original Assignee
MedImmune Ltd
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd, Sanofi Pasteur Inc filed Critical MedImmune Ltd
Publication of CA3138180A1 publication Critical patent/CA3138180A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
CA3138180A 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies Pending CA3138180A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840,701 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Publications (1)

Publication Number Publication Date
CA3138180A1 true CA3138180A1 (en) 2020-11-05

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3138180A Pending CA3138180A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Country Status (15)

Country Link
US (3) US12024553B2 (https=)
EP (1) EP3962940A1 (https=)
JP (2) JP2022531205A (https=)
KR (1) KR20220002427A (https=)
CN (1) CN113825767A (https=)
AU (1) AU2020265676A1 (https=)
BR (1) BR112021020846A2 (https=)
CA (1) CA3138180A1 (https=)
CO (1) CO2021014370A2 (https=)
EA (1) EA202192776A1 (https=)
IL (1) IL287443A (https=)
MX (1) MX2021013248A (https=)
SG (1) SG11202111748TA (https=)
TW (1) TWI861099B (https=)
WO (1) WO2020223435A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2023039584A2 (en) * 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物

Also Published As

Publication number Publication date
EA202192776A1 (ru) 2022-01-19
JP2025072444A (ja) 2025-05-09
TWI861099B (zh) 2024-11-11
US20220204593A1 (en) 2022-06-30
JP2022531205A (ja) 2022-07-06
CN113825767A (zh) 2021-12-21
WO2020223435A1 (en) 2020-11-05
TW202106333A (zh) 2021-02-16
AU2020265676A1 (en) 2021-11-18
SG11202111748TA (en) 2021-11-29
BR112021020846A2 (pt) 2022-01-18
US20240417447A1 (en) 2024-12-19
US20200347120A1 (en) 2020-11-05
CO2021014370A2 (es) 2021-10-29
EP3962940A1 (en) 2022-03-09
KR20220002427A (ko) 2022-01-06
MX2021013248A (es) 2022-01-24
IL287443A (en) 2021-12-01
US12024553B2 (en) 2024-07-02

Similar Documents

Publication Publication Date Title
US20240417447A1 (en) Dosage regimens for and compositions including anti-rsv antibodies
AU2021202598B2 (en) Compositions and methods for the treatment of immunodeficiency
Mejias et al. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
WO2015131836A1 (zh) 一种h7型甲型流感病毒的中和抗体及其用途
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
AU2017222564A1 (en) Formulations of antibody molecules to influenza virus
US20240228596A1 (en) Pan-specific corona virus binders
JP2023554456A (ja) 呼吸器合胞体ウイルスに特異的に結合する分子
AU2022361501B2 (en) Anti-sars-cov-2 antibodies and uses thereof i
US20240400653A1 (en) Anti-sars-cov-2 antibodies and uses thereof i
JP2025542128A (ja) メタニューモウイルス融合（ｆ）タンパク質に対する抗体及びその使用
EA046902B1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
US20240043524A1 (en) Interleukin 5 binding protein dosage regimen
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
RU2807524C2 (ru) Составы антител к rsv и способы их применения
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
WO2023172881A1 (en) Hmpv antibodies and their use
WO2022079001A2 (en) Sars-cov-2 antigens, diagnostic and therapeutic uses
AU2024264265A1 (en) Anti-influenza antibody
WO2021005232A1 (en) Intranasal administration of neutralising antiviral antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250325

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250325

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250325

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251008

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260218